1-15 of 15
Jeffrey A. Engelman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer

Carlotta Costa, Ye Wang, Amy Ly, Yasuyuki Hosono, Ellen Murchie, Charlotte S. Walmsley, Tiffany Huynh, Christopher Healy, Rachel Peterson, Shogo Yanase, Charles T. Jakubik, Laura E. Henderson, Leah J. Damon, Daria Timonina, Ioannis Sanidas, Christopher J. Pinto, Mari Mino-Kenudson, James R. Stone, Nicholas J. Dyson, Leif W. Ellisen, Aditya Bardia, Hiromichi Ebi, Cyril H. Benes, Jeffrey A. Engelman, Dejan Juric
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2020) 10 (1): 72–85.
https://doi.org/10.1158/2159-8290.CD-18-0830
Published: 09 January 2020
View article titled, PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Open the PDF for PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

Satoshi Yoda, Jessica J. Lin, Michael S. Lawrence, Benjamin J. Burke, Luc Friboulet, Adam Langenbucher, Leila Dardaei, Kylie Prutisto-Chang, Ibiayi Dagogo-Jack, Sergei Timofeevski, Harper Hubbeling, Justin F. Gainor, Lorin A. Ferris, Amanda K. Riley, Krystina E. Kattermann, Daria Timonina, Rebecca S. Heist, A. John Iafrate, Cyril H. Benes, Jochen K. Lennerz, Mari Mino-Kenudson, Jeffrey A. Engelman, Ted W. Johnson, Aaron N. Hata, Alice T. Shaw
Journal: Cancer Discovery
Cancer Discov (2018) 8 (6): 714–729.
https://doi.org/10.1158/2159-8290.CD-17-1256
Published: 31 May 2018
View article titled, Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <em>ALK</em> Mutations in ALK-Positive Lung Cancer
Open the PDF for Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <em>ALK</em> Mutations in ALK-Positive Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers

Carl U. Bialucha, Scott D. Collins, Xiao Li, Parmita Saxena, Xiamei Zhang, Clemens Dürr, Bruno Lafont, Pierric Prieur, Yeonju Shim, Rebecca Mosher, David Lee, Lance Ostrom, Tiancen Hu, Sanela Bilic, Ivana Liric Rajlic, Vladimir Capka, Wei Jiang, Joel P. Wagner, GiNell Elliott, Artur Veloso, Jessica C. Piel, Meghan M. Flaherty, Keith G. Mansfield, Emily K. Meseck, Tina Rubic-Schneider, Anne Serdakowski London, William R. Tschantz, Markus Kurz, Duc Nguyen, Aaron Bourret, Matthew J. Meyer, Jason E. Faris, Mary J. Janatpour, Vivien W. Chan, Nicholas C. Yoder, Kalli C. Catcott, Molly A. McShea, Xiuxia Sun, Hui Gao, Juliet Williams, Francesco Hofmann, Jeffrey A. Engelman, Seth A. Ettenberg, William R. Sellers, Emma Lees
Journal: Cancer Discovery
Cancer Discov (2017) 7 (9): 1030–1045.
https://doi.org/10.1158/2159-8290.CD-16-1414
Published: 31 August 2017
View article titled, Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers
Open the PDF for Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers in another window
Includes: Supplementary data
Journal Articles

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

Justin F. Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh, Emily Chin, Melissa Parks, Dana Lee, Richard H. DiCecca, Elizabeth Lockerman, Tiffany Huynh, Jennifer Logan, Lauren L. Ritterhouse, Long P. Le, Ashok Muniappan, Subba Digumarthy, Colleen Channick, Colleen Keyes, Gad Getz, Dora Dias-Santagata, Rebecca S. Heist, Jochen Lennerz, Lecia V. Sequist, Cyril H. Benes, A. John Iafrate, Mari Mino-Kenudson, Jeffrey A. Engelman, Alice T. Shaw
Journal: Cancer Discovery
Cancer Discov (2016) 6 (10): 1118–1133.
https://doi.org/10.1158/2159-8290.CD-16-0596
Published: 02 October 2016
View article titled, Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <em>ALK</em>-Rearranged Lung Cancer
Open the PDF for Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <em>ALK</em>-Rearranged Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

Zofia Piotrowska, Matthew J. Niederst, Chris A. Karlovich, Heather A. Wakelee, Joel W. Neal, Mari Mino-Kenudson, Linnea Fulton, Aaron N. Hata, Elizabeth L. Lockerman, Anuj Kalsy, Subba Digumarthy, Alona Muzikansky, Mitch Raponi, Angel R. Garcia, Hillary E. Mulvey, Melissa K. Parks, Richard H. DiCecca, Dora Dias-Santagata, A. John Iafrate, Alice T. Shaw, Andrew R. Allen, Jeffrey A. Engelman, Lecia V. Sequist
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2015) 5 (7): 713–722.
https://doi.org/10.1158/2159-8290.CD-15-0399
Published: 06 July 2015
View article titled, Heterogeneity Underlies the Emergence of <em>EGFR</em><sup>T790</sup> Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Open the PDF for Heterogeneity Underlies the Emergence of <em>EGFR</em><sup>T790</sup> Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor in another window
Includes: Supplementary data
Journal Articles

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

Aaron N. Hata, Jeffrey A. Engelman, Anthony C. Faber
Journal: Cancer Discovery
Cancer Discov (2015) 5 (5): 475–487.
https://doi.org/10.1158/2159-8290.CD-15-0011
Published: 03 May 2015
View article titled, The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Open the PDF for The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics in another window
Journal Articles

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations

Leanne G. Ahronian, Erin M. Sennott, Eliezer M. Van Allen, Nikhil Wagle, Eunice L. Kwak, Jason E. Faris, Jason T. Godfrey, Koki Nishimura, Kerry D. Lynch, Craig H. Mermel, Elizabeth L. Lockerman, Anuj Kalsy, Joseph M. Gurski, Jr, Samira Bahl, Kristin Anderka, Lisa M. Green, Niall J. Lennon, Tiffany G. Huynh, Mari Mino-Kenudson, Gad Getz, Dora Dias-Santagata, A. John Iafrate, Jeffrey A. Engelman, Levi A. Garraway, Ryan B. Corcoran
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2015) 5 (4): 358–367.
https://doi.org/10.1158/2159-8290.CD-14-1518
Published: 05 April 2015
View article titled, Clinical Acquired Resistance to RAF Inhibitor Combinations in <em>BRAF</em>-Mutant Colorectal Cancer through MAPK Pathway Alterations
Open the PDF for Clinical Acquired Resistance to RAF Inhibitor Combinations in <em>BRAF</em>-Mutant Colorectal Cancer through MAPK Pathway Alterations in another window
Includes: Supplementary data
Journal Articles

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

Luc Friboulet, Nanxin Li, Ryohei Katayama, Christian C. Lee, Justin F. Gainor, Adam S. Crystal, Pierre-Yves Michellys, Mark M. Awad, Noriko Yanagitani, Sungjoon Kim, AnneMarie C. Pferdekamper, Jie Li, Shailaja Kasibhatla, Frank Sun, Xiuying Sun, Su Hua, Peter McNamara, Sidra Mahmood, Elizabeth L. Lockerman, Naoya Fujita, Makoto Nishio, Jennifer L. Harris, Alice T. Shaw, Jeffrey A. Engelman
Journal: Cancer Discovery
Cancer Discov (2014) 4 (6): 662–673.
https://doi.org/10.1158/2159-8290.CD-13-0846
Published: 01 June 2014
View article titled, The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Open the PDF for The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit

Zehua Zhu, Amir R. Aref, Travis J. Cohoon, Thanh U. Barbie, Yu Imamura, Shenghong Yang, Susan E. Moody, Rhine R. Shen, Anna C. Schinzel, Tran C. Thai, Jacob B. Reibel, Pablo Tamayo, Jason T. Godfrey, Zhi Rong Qian, Asher N. Page, Karolina Maciag, Edmond M. Chan, Whitney Silkworth, Mary T. Labowsky, Lior Rozhansky, Jill P. Mesirov, William E. Gillanders, Shuji Ogino, Nir Hacohen, Suzanne Gaudet, Michael J. Eck, Jeffrey A. Engelman, Ryan B. Corcoran, Kwok-Kin Wong, William C. Hahn, David A. Barbie
Journal: Cancer Discovery
Cancer Discov (2014) 4 (4): 452–465.
https://doi.org/10.1158/2159-8290.CD-13-0646
Published: 03 April 2014
View article titled, Inhibition of <em>KRAS</em>-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit
Open the PDF for Inhibition of <em>KRAS</em>-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit in another window
Includes: Supplementary data
Journal Articles

mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1

Anthony C. Faber, Erin M. Coffee, Carlotta Costa, Anahita Dastur, Hiromichi Ebi, Aaron N. Hata, Alan T. Yeo, Elena J. Edelman, Youngchul Song, Ah Ting Tam, Jessica L. Boisvert, Randy J. Milano, Jatin Roper, David P. Kodack, Rakesh K. Jain, Ryan B. Corcoran, Miguel N. Rivera, Sridhar Ramaswamy, Kenneth E. Hung, Cyril H. Benes, Jeffrey A. Engelman
Journal: Cancer Discovery
Cancer Discov (2014) 4 (1): 42–52.
https://doi.org/10.1158/2159-8290.CD-13-0315
Published: 07 January 2014
View article titled, mTOR Inhibition Specifically Sensitizes Colorectal Cancers with <em>KRAS</em> or <em>BRAF</em> Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
Open the PDF for mTOR Inhibition Specifically Sensitizes Colorectal Cancers with <em>KRAS</em> or <em>BRAF</em> Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 in another window
Includes: Supplementary data
Journal Articles

Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in LKB1-Mutant Lung Cancer

Yan Liu, Kevin Marks, Glenn S. Cowley, Julian Carretero, Qingsong Liu, Thomas J.F. Nieland, Chunxiao Xu, Travis J. Cohoon, Peng Gao, Yong Zhang, Zhao Chen, Abigail B. Altabef, Jeremy H. Tchaicha, Xiaoxu Wang, Sung Choe, Edward M. Driggers, Jianming Zhang, Sean T. Bailey, Norman E. Sharpless, D. Neil Hayes, Nirali M. Patel, Pasi A. Janne, Nabeel Bardeesy, Jeffrey A. Engelman, Brendan D. Manning, Reuben J. Shaw, John M. Asara, Ralph Scully, Alec Kimmelman, Lauren A. Byers, Don L. Gibbons, Ignacio I. Wistuba, John V. Heymach, David J. Kwiatkowski, William Y. Kim, Andrew L. Kung, Nathanael S. Gray, David E. Root, Lewis C. Cantley, Kwok-Kin Wong
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2013) 3 (8): 870–879.
https://doi.org/10.1158/2159-8290.CD-13-0015
Published: 07 August 2013
View article titled, Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in <em>LKB1</em>-Mutant Lung Cancer
Open the PDF for Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in <em>LKB1</em>-Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

Ryan B. Corcoran, Hiromichi Ebi, Alexa B. Turke, Erin M. Coffee, Michiya Nishino, Alexandria P. Cogdill, Ronald D. Brown, Patricia Della Pelle, Dora Dias-Santagata, Kenneth E. Hung, Keith T. Flaherty, Adriano Piris, Jennifer A. Wargo, Jeffrey Settleman, Mari Mino-Kenudson, Jeffrey A. Engelman
Journal: Cancer Discovery
Cancer Discov (2012) 2 (3): 227–235.
https://doi.org/10.1158/2159-8290.CD-11-0341
Published: 13 March 2012
View article titled, EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <em>BRAF</em>-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Open the PDF for EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <em>BRAF</em>-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib in another window
Includes: Supplementary data
Journal Articles

Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung Cancers

Hiu Wing Cheung, Jinyan Du, Jesse S. Boehm, Frank He, Barbara A. Weir, Xiaoxing Wang, Mohit Butaney, Lecia V. Sequist, Biao Luo, Jeffrey A. Engelman, David E. Root, Matthew Meyerson, Todd R. Golub, Pasi A. Jänne, William C. Hahn
Journal: Cancer Discovery
Cancer Discov (2011) 1 (7): 608–625.
https://doi.org/10.1158/2159-8290.CD-11-0046
Published: 13 December 2011
View article titled, Amplification of <em>CRKL</em> Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung Cancers
Open the PDF for Amplification of <em>CRKL</em> Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung Cancers in another window
Includes: Supplementary data
Journal Articles

BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors

Anthony C. Faber, Ryan B. Corcoran, Hiromichi Ebi, Lecia V. Sequist, Belinda A. Waltman, Euiheon Chung, Joao Incio, Subba R. Digumarthy, Sarah F. Pollack, Youngchul Song, Alona Muzikansky, Eugene Lifshits, Sylvie Roberge, Erik J. Coffman, Cyril H. Benes, Henry L. Gómez, José Baselga, Carlos L. Arteaga, Miguel N. Rivera, Dora Dias-Santagata, Rakesh K. Jain, Jeffrey A. Engelman
Journal: Cancer Discovery
Cancer Discov (2011) 1 (4): 352–365.
https://doi.org/10.1158/2159-8290.CD-11-0106
Published: 14 September 2011
View article titled, BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors
Open the PDF for BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors in another window
Includes: Multimedia, Supplementary data
Journal Articles

A New BATTLE in the Evolving War on Cancer

Lecia V. Sequist, Alona Muzikansky, Jeffrey A. Engelman
Journal: Cancer Discovery
Cancer Discov (2011) 1 (1): 14–16.
https://doi.org/10.1158/2159-8274.CD-11-0044
Published: 01 June 2011
View article titled, A New BATTLE in the Evolving War on Cancer
Open the PDF for A New BATTLE in the Evolving War on Cancer in another window